Member Info for cottoner

Coronavirus: Waste water at sewage works tested in Covid-19 trial
By Kevin Keane BBC Scotland's environment correspondent
22 June 202

A trial is under way to test waste water for signs of Covid-19 in a bid to help pinpoint local spikes of the virus.

The samples are being taken at sewage treatment works in each of Scotland's 14 NHS health board areas.

They are then tested for fragments of Covid-19 in ribonucleic acid (RNA) which is produced by the body.

If successful, the results could be used by government ministers as part of their response to the pandemic.

The Scottish Environment Protection Agency (Sepa) said it was one of the first agencies in Europe to carry out this type of work.

'Early stages'

The samples will be taken at Scottish Water sites and tested by Sepa using methods developed by scientists at the Roslin Institute in Edinburgh.

Sepa chief executive, Terry A'Hearn, said the body was "in the early stages of this exploratory work".

"Our expertise in designing and implementing monitoring networks, coupled with our scientific capabilities, meant that we were able to get up and running quickly with the support of our partners," he said.

"Our hope is that our analysis could provide useful data in Scotland's efforts to trace the virus.

"However, we first have to understand what the samples are telling us and that's the important work our experts, alongside Health Protection Scotland, The Roslin Institute and others in the scientific community are embarking on now."

continues...

https://www.bbc.co.uk/news/uk-scotland-53109139

Further to the recent statement made by James Benamor on social media on 4 June 2020, following clarification of Richmond Group Limited's ("Richmond") intentions, Amigo has been told by Richmond that:



(i) Richmond has placed all of its shares in Amigo with a broker, with irrevocable instructions to sell 1% of the company every trading day until Richmond's stake is reduced to zero, in the event that the current board remain in place after the upcoming general meeting on 17 June 2020 (the "General Meeting"); and



(ii) there are no circumstances in which those sell-instructions can be cancelled or amended by Richmond.



Richmond have noted that notwithstanding the irrevocable instruction to sell, Richmond is able to sell shares before the General Meeting, as the irrevocable sell instruction only applies to the shares Richmond still owns at the time of the vote.

Bronxville,

My final word on the subject.

There were two stages of the Phase 1 AG-S trial with partial results being issued in 2018.
The Lancet have just published the completed results.

From OO website :

AGs-V - Phase 1b study completed by NIH - Preliminary resultys positive, completed results expected in due course
AGs-PLUS Second Phase 1 study commenced July 19 (2019) by NIH - additional peptide
AGS-v, a phase I vaccine candidate for all mosquito saliva borne disease

AGS-v is a mosquito-borne disease vaccine with a novel proposed dual action mechanism of preventing infection in humans whilst controlling the mosquito population. AGS-v is composed of four salivary peptides isolated from Anopheles gambiae salivary glands, but that are common across a number of mosquitoes.

In 2018, the NIH presented partial results from the Phase I first-in-man study of AGS-v completed by the NIH. Based upon currently available data the Phase I study met primary objective endpoints with regard to safety and humoral response.

The remaining endpoints will be evaluated once the full and final data are available in due course, at which point a full assessment of the trial results will be possible when the NIH completes the sample analyses.

Timeline :
July 21st 2017 - HVIVO RNS - Initiation of a Phase I clinical trial with AGS-v

Oct 31st 2018 - HVIVO RNS - Partial preliminary results for NIH study of AGS-v

Trevor Phillips, Executive Chairman of hVIVO, said: "The presentation of these partial preliminary results by NIH at the ASTMH conference is encouraging regarding safety and immunogenicity responses. We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible".

Juky 31st 2019 - HVIVO RNS - Phase 1 clinical trial of AGS-v PLUS

Trevor Phillips, Executive Chairman of hVIVO, said: "It is great to see the relationship with NIH and the University of Maryland School of Medicine continues as AGS-v PLUS, one of the assets in our joint venture Imutex, moves into the clinic. We are pleased that the development of this asset is continuing with NIAID-funded researchers testing the vaccine and additional funding for the study by Innovate UK"

June 2020 - Lancet publish completed results of Phase 1

With regard to FLU-V , Noboby is disputing that it is more advanced than the AGS Mosquito vaccine candidate.
FLU-V has completed Phase II and is Phase III ready , whereas AGS has just completed Phase I.

However the results from the AGS-v Phase I study are more recent having just been published in the Lancet.

Surely the trial ends when the results have been published.

It's not when the trial starts that counts , it's the results at the end of it.

What the Lancet has published is findings from now , not from 2017.

I think there's no doubt the Lancet paper is taling about the SEEK/HVIVO trial.

From Lancet report:

In the double-blind study, 49 healthy participants were enrolled at the National Institutes of Health Clinical Center in Bethesda, Md.

From HVIVO RNS Reach July 31st 2019

AGS-v PLUS wasdeveloped by Imutex Limited, hVIVO's49% joint venture with the SEEK Group-The trial will be conducted by the National Institutes of Health (NIH) and will take place at the University of Maryland School of Medicine

Can't see how the acquirer of the 25 millions shares was PIs , as Acacia only got them from Link on Monday the 8th.
There was the 25 million trade yesterday.
If PIs had bought them there would have to be a huge amount volume of trades yesterday.
There wasn't.
So how could the PIs have taken them?

Please explain.

Of course there is always the possibility that a large trade(s) have not been shown and could appear days later.

Wouldn't be the first time that has happened.

Open orphan have retweeted Quotient photo saying

WE DOUBLED OUR BATCH SIZE

SEE EML RNS issued 24th Sept 2019

Extracts:

Consolidation of 21 core mineral exploration permits of the Khemisset Potash Project into a single project permit has been approved and authorised

· Emmerson's Moroccan subsidiary is one of the first mining companies in Morocco to achieve an authorisation for the consolidation of permits under the new Moroccan Mining Code

· Significantly simplifies Emmerson's in-country technical reporting and administration processes ahead of its eventual application for the mining permits

His Excellence, Mr Aziz Rabbah, Minster of Energy, Mines and Sustainable Development, commented:

"The Kingdom of Morocco implemented its new mining code in 2015 to provide a strong platform to facilitate and simplify the administrative procedures for local and overseas companies, with expertise in mining, to invest in our vast, largely untapped, mineral resources. We are strongly supportive of companies that approach investment in our country in the right manner, targeting the development of long term, sustainable businesses for the benefit of all stakeholders."

Hayden Locke, CEO of Emmerson, commented:

"The Moroccan Government and, in particular, the Ministry of Energy, Mines and Sustainable Development, continue to offer strong support to Emmerson, providing us with a high degree of confidence in our ability to advance the world class Khemisset Potash Project forward.

"The consolidation of the permits is the first step for the Company in the eventual process to apply for a mining permit over the Project. It also assists in reducing the ongoing administrative reporting burden. The Ministry's continued support will be instrumental in the permitting phase and as we develop our social license to operate in the Khemisset region.

Consolidation of Khemisset Project Exploration Permits into Single Permit Approved,
ahead of Mining Permit Application

Duplication my error! :-)

“I took the antibody test that could help get millions back to work – by revealing they’ve had #Covid WITHOUT realising”
“I took the antibody test that could help get millions back to work – by revealing they’ve had #Covid WITHOUT realising”

?@TheSun? was one of several press outlets to cover our launch and we look forward to seeing more coverage over the coming weeks

Ince strengthens global shipping team with the hire of Clyde & Co Partner, Stuart McAlpine
05/06/2020

International law firm Ince has today announced the appointment of Stuart McAlpine as Partner within the Marine team.

In his role as Global Head of Marine Projects and Finance, Stuart will focus on further strengthening Ince’s position within the marine sector and growing its legal services offering globally.

Stuart is a well known and highly respected figure in the shipping world with more than 30 years’ experience advising clients in London, Singapore and Paris. He is a highly experienced maritime lawyer, gaining significant expertise from working on complex, cross border transactions in the maritime and energy industries, in particular gas and LNG. Stuart’s experience has seen him being recognised as one of the top ten maritime lawyers of 2018 by Lloyd’s List.

He is the latest in a number of significant hires for Ince. In recent months, the company announced Julian Clark as Senior Partner, Mark Tantam as Global Head of Consulting, Alexander Janes as Head of EMEA.

Ince’s maritime division was also bolstered further earlier this year with the arrival of ten fee earners from specialist shipping law firm Bentleys, Stokes and Lowless who joined the team in London.

Commenting on the appointment, Adrian Biles, Chief Executive of The Ince Group said:

“Ince is committed to maintaining the best global shipping team in the market. Stuart is a
hugely experienced and respected lawyer, who has dedicated decades of his life to the maritime and energy industries. His deep understanding and knowledge of these industries will be invaluable for Ince as we continue to develop and grow”

Speaking on his new role, Stuart McAlpine said:

“Ince’s hard fought reputation in the sector is renowned and demonstrates the high quality of its lawyers. I look forward to working as part of an industry leading team and utilising my experience to help the firm prosper.”
Source: Ince & Co.

https://www.hellenicshippingnews.com/ince-strengthens-global-shipping-team-with-the-hire-of-clyde-co-partner-stuart-mcalpine/

I'd disagree.
So far I'd say it's been
Deliver, Deliver, Deliver

NXP004

The Company has commenced pre-clinical pilot studies to investigate the potential for NXP004 as a treatment for multiple forms of fibrosis in various human tissues with its research partner,

Initial data received is very promising and suggests NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies.

FROM PRTC's RNS today:

Emerging data suggest many of the millions infected with COVID-19 may be at risk for long-term pulmonary dysfunction, including fibrosis

"Hundreds of clinical trials are underway to combat COVID-19, but the vast majority are focused on vaccines or the acute treatment of severe patients," said Dennis Ausiello, MD, former chief of medicine at Massachusetts General Hospital and a member of the PureTech R&D Committee. "As we learn more about the full impact of COVID-19 on the body, we're seeing post-recovery, longer-term pulmonary dysfunction similar to that observed following infection with other coronaviruses, including SARS and MERS. In fact, emerging data suggest that a high proportion of COVID-19 patients are at risk of impaired lung function and fibrosis after recovery, as well as during acute infection. With more than five million documented infections to date worldwide, there is a clear and urgent need for therapeutics to address the longer-term sequalae of COVID-19."

The IIs who have over subcribed by 5 times the placing shares allocated to them will have been given far more information on ORPH's current and future plans than any PI currently knows.
They will also have been given some specific money numbers going forward.

Thus, the fact the IIs were 'knocking the ORPH doors down' to get shares says enough for me.

As the Quotient test has been developed by their scientists in Midlothian , Scotland it would be logical for the Scottish government to use them , especially given their accuracy.

https://www.edinburghlive.co.uk/news/edinburgh-news/new-fast-accurate-coronavirus-antibody-18192701

Item below highlights one scenario where ORPH test will be in demand.

Coronavirus: Travellers charged €190 at Vienna airport to avoid 14-day COVID-19 quarantine

Travellers wanting to enter Austria and avoid a two-week quarantine are being charged €190 to prove they are free of COVID-19.

Austria says anyone arriving at its airports or land borders without proof they are coronavirus-free must go into isolation.

If travellers don't have proof, they can pay €190 for a test at Vienna airport

https://www.euronews.com/2020/05/06/coronavirus-travellers-charged-190-at-vienna-airport-to-avoid-14-day-covid-19-quarantine

CF said placing was 5 times over subscribed.

Because it was bought at below the MID PRICE, thus it has shown as a SELL.

Any trades below mid-price will show as a SELL.
Any trades above mid-price will show as a BUY.